Company

OUR VISION

To improve human health by accelerating the world’s transition to precision medicine

OUR MISSION

To improve the success of drug discovery and development through Genomics, AI and Quantum Computing

EXECUTIVE SUMMARY

THE PROBLEM

“The ability to generate a very good quality technical sequence of the human genome exists. But there is a massive gap between having the data in front of us and knowing what it all means”.

Quote from December 2020 interview with Dr. Eric Green, head of the National Human Genome Research Institute (Leading US genomic research organization.)

The life sciences industry is under pressure due to increasing costs and time required to bring average drug to market. Traditional methods of conducting clinical trials may not be sustainable as high rates of failure exceed revenues from new drugs.

OUR SOLUTION

Collaboration with Fortune 100 company for groundbreaking development of biological digital twins embedded with proprietary genetic and epigenetic analytics as well as generative AI and quantum computing.

Rich Dataset

The dataset derived from over 15,000 case studies is a substantial and diverse source of information. Including a wide range of genetic, environmental, lifestyle, and health-related data, making it a valuable resource for understanding the underlying causes of diseases and cellular behavior.

Factors Influencing Cellular Behavior

GNQ's approach takes a comprehensive approach essential for gaining insights into complex diseases including factors influencing cellular behaviours such as genetic pathways, environmental factors, lifestyle choices, diet, exercise, and more.

Genomics, AI, and Quantum Computing

The integration of genomics, AI, and quantum computing represents a cutting-edge approach to drug discovery and development. Genomics provides insights into the genetic basis of diseases, AI can analyze and interpret vast datasets, and quantum computing can tackle complex simulations and calculations that were previously challenging.

Novel Approach

GNQ's platform introduces a novel approach to drug discovery. By leveraging deep genomic understanding and advanced technologies, it has the potential to identify novel drug targets, optimize drug molecules, and predict treatment responses with greater precision.

Accelerated Research

The combination of proprietary genomic insights and advanced technologies can significantly accelerate the research and development process. This can lead to faster discoveries and potentially more effective treatments for a wide range of diseases.

Ethical and Privacy Considerations

Given the sensitive nature of genomic and health data, it's crucial for GNQ to maintain rigorous ethical standards and data privacy measures to protect individuals' information.

Collaboration and Validation

Collaborations with research institutions, clinical experts, and regulatory bodies are essential for validating the findings and ensuring that they meet regulatory standards for drug development.

Previous slide

Next slide

THE OPPORTUNITY

Platform is expected to dramatically cuts costs as well as reduce development time for new therapeutics. Potential annual savings of billions of dollars in research and development costs for world’s leading life science companies.

Platform Licensing Opportunities

Being a pioneer in this space allows GNQ to explore platform licensing opportunities. Licensing its proprietary technologies, insights, or platforms to other pharmaceutical companies, research institutions, or startups will create new revenue streams and establish GNQ as a leader in the industry.

Collaborations with Strategic Partners

Partnering with key players in the life sciences and healthcare industries can provide access to resources, expertise, and distribution channels. Collaborations can enhance research capabilities, accelerate product development, and broaden the reach of GNQ's innovations.

Research and Development Acceleration

GNQ's first-mover advantage positions it to lead in innovative drug discovery methods. This can result in faster and more efficient research and development processes, leading to a competitive edge in bringing new therapies to market.

Market Leadership

By establishing itself as a first mover, GNQ will build a strong reputation and credibility in the industry. This leadership position attracts talent, investors, and potential partners interested in being part of a ground-breaking endeavor.

Diversification of Offerings

Beyond drug discovery, GNQ can diversify its offerings by exploring applications in diagnostics, personalized medicine, and healthcare analytics. This diversification can provide resilience and opportunities for growth.

Long-Term Vision

GNQ has a clear long-term vision for its role in the drug discovery and healthcare ecosystem. This includes planning for scalability, sustainability, and adaptation to evolving technologies and market dynamics.

Customer-Centric Approach

GNQ prioritizes a customer-centric approach by tailoring solutions to meet the specific needs of clients in the life sciences and healthcare industries. Understanding their pain points and offering solutions that address them is key to success.

Previous slide

Next slide

LEADERSHIP

Rehan Huda

Co-Founder, Chairperson, Board of Directors and Chief Executive Officer

Has structured numerous public offerings in Canada & the US as investment banking advisor, founder and board member.
Former senior economist with Canadian federal government and a frequent guest speaker at various international finance and economics conferences.
Previously CEO of Green Sky Labs, a technology incubation company.

Sudhir Saxena

Chief Technology Officer

Big 4 Technology leader (IBM, Accenture…) focused on executing Technology based Go-to-Market strategies in Healthcare & Life Sciences.
Experienced in Exponential technologies (AI, Blockchain and IOT), to leverage health data as an asset and scale human centered AI across all healthcare facets.
Serial entrepreneur and angel investor, with track record in building & growing technology startups.

Asif Mustafa

Chief Financial Officer

Over 20 years of experience in finance, risk management, governance, audit, compliance and technology.
Held senior finance, operations and change management roles in big Pharma, Wall Street and Big 4 Consulting. Has also held management roles in corporate development, M&A and FP&A in Fortune 100 companies.
Technology product management, development and pre-sales experience for major software platform.

Dr. Jerome Schentag

Chief Operating Officer

Clinical Pharmacology PK/PD specialist with broad expertise in Anti-infectives, Cardio-metabolic and Immuno-Oncology drug development and regulatory sciences.
Inventor holding over 90 patents on biologics, drugs medical devices and drug delivery technologies.
Founder of TheraSyn and Synergy Therapeutics, actively developing solutions for tumor diagnosis and treatments

COMPANY